Rate of Pathologic Complete Responses to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
Robert I. Haddad(Georgetown University), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Laura A. Goguen(Brigham and Women's Hospital), Charles M. Norris, Roy B. Tishler(Dana-Farber Cancer Institute), Yi Li(Tongji Hospital), Lori J. Wirth(Massachusetts General Hospital), Christopher A. Sullivan(Brigham and Women's Hospital), Lindsay O’Donnell
Cited by 28
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926